Equity Profile

AZN

AstraZeneca PLC

Health CarePharmaceuticals$262.8B

Feb10Tue

Pre-Earnings Brief

UpcomingQ1-2018Pre-Market9:00 AM EST

Company Snapshot

AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Operating in the Health Care sector, AstraZeneca is known for its innovative treatments in areas like oncology, cardiovascular, and respiratory diseases, making it a significant player in the pharmaceuticals industry.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and is closely watched by investors to gauge financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is critical for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q1-2018 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

In Q4 2017, AstraZeneca reported an EPS of $1.30, significantly beating estimates by 66.36%. The stock reacted positively, gaining 2.16% the following day.

Management Promises & Guidance

Focus on expanding oncology portfolio.
Commitment to improving operational efficiency.
Plans to enhance pipeline productivity.

Expectations

Wall Street Expectations

Overall, expectations for AstraZeneca are cautiously optimistic, given its recent strong performance and focus on innovation.

Bull Case

If AstraZeneca continues to deliver strong earnings and shows significant revenue growth, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of slowing growth, it could result in a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter?

Earnings per share is a critical measure of profitability, and any significant deviation from expectations could impact stock performance.

How is the revenue growth trajectory for the oncology segment?

Given the focus on oncology, insights into this segment's performance will be crucial for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AstraZeneca's growth potential in oncology, as recent pipeline developments suggest stronger-than-expected demand.

Supporting Evidence

The company's recent product launches have shown promising early sales figures.

Options pricing indicates a significant expected move, suggesting that traders anticipate volatility based on upcoming news.

Key Risk

If the oncology segment shows unexpected growth, it could challenge current bearish sentiments.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on AstraZeneca's ability to meet or exceed earnings expectations, particularly in its key therapeutic areas.

Bull Confirmed If

A strong EPS of $1.50 or better would confirm the bull case, indicating robust profitability.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, raising concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±4.2%

In line with history

The options market is pricing in a potential move of about 4.3%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±4.3% while AZN has averaged ±4.2% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

20.7%

Calls (35K)P/C Ratio: 1.14Puts (91K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests the stock could rise by around 1.01% on the following day, confirming investor confidence.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see muted movement as investors reassess future growth.

Miss

A miss on earnings could lead to a decline of approximately 1.06%, as investors react negatively to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the oncology pipeline and expected product launches.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and operational efficiencies.
4Insights into competitive positioning in key therapeutic areas.
5Any commentary on regulatory developments affecting product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ORIX Corporation

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and is closely watched by investors to gauge financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is critical for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q1-2018 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

In Q4 2017, AstraZeneca reported an EPS of $1.30, significantly beating estimates by 66.36%. The stock reacted positively, gaining 2.16% the following day.

Management Promises & Guidance

Focus on expanding oncology portfolio.
Commitment to improving operational efficiency.
Plans to enhance pipeline productivity.

Expectations

Wall Street Expectations

Overall, expectations for AstraZeneca are cautiously optimistic, given its recent strong performance and focus on innovation.

Bull Case

If AstraZeneca continues to deliver strong earnings and shows significant revenue growth, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company fails to meet earnings expectations or shows signs of slowing growth, it could result in a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter?

Earnings per share is a critical measure of profitability, and any significant deviation from expectations could impact stock performance.

How is the revenue growth trajectory for the oncology segment?

Given the focus on oncology, insights into this segment's performance will be crucial for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AstraZeneca's growth potential in oncology, as recent pipeline developments suggest stronger-than-expected demand.

Supporting Evidence

The company's recent product launches have shown promising early sales figures.

Options pricing indicates a significant expected move, suggesting that traders anticipate volatility based on upcoming news.

Key Risk

If the oncology segment shows unexpected growth, it could challenge current bearish sentiments.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on AstraZeneca's ability to meet or exceed earnings expectations, particularly in its key therapeutic areas.

Bull Confirmed If

A strong EPS of $1.50 or better would confirm the bull case, indicating robust profitability.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, raising concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±4.2%

In line with history

The options market is pricing in a potential move of about 4.3%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±4.3% while AZN has averaged ±4.2% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

20.7%

Calls (35K)P/C Ratio: 1.14Puts (91K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests the stock could rise by around 1.01% on the following day, confirming investor confidence.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see muted movement as investors reassess future growth.

Miss

A miss on earnings could lead to a decline of approximately 1.06%, as investors react negatively to disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the oncology pipeline and expected product launches.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies and operational efficiencies.
4Insights into competitive positioning in key therapeutic areas.
5Any commentary on regulatory developments affecting product approvals.